Survival with cetuximab/FOLFOX or cetuximab/FOLFIRI of patients with nonresectable colorectal liver metastases in the CELIM study.
Gunnar Folprecht
Consultant or Advisory Role - Bristol-Myers Squibb; Merck KGaA; Roche/Genentech
Honoraria - Amgen; Merck KGaA; Roche
Research Funding - Merck KGaA; Pfizer; Sanofi
Thomas Gruenberger
No relevant relationships to disclose
Wolf Bechstein
No relevant relationships to disclose
Florian Lordick
No relevant relationships to disclose
Hauke Lang
No relevant relationships to disclose
Jürgen Weitz
No relevant relationships to disclose
Thomas Suedhoff
No relevant relationships to disclose
Joerg Thomas Hartmann
No relevant relationships to disclose
Torsten Liersch
No relevant relationships to disclose
Claus-Henning Kohne
No relevant relationships to disclose